Im Cannabis Net Income From Continuing Ops Over Time
| IMCC Stock | USD 1.21 0.07 5.47% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Im Cannabis Performance and Im Cannabis Correlation. Will Biotechnology sector continue expanding? Could IMCC diversify its offerings? Factors like these will boost the valuation of Im Cannabis. Market participants price IMCC higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Im Cannabis data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.50) | Revenue Per Share | Quarterly Revenue Growth (0) | Return On Assets | Return On Equity |
Understanding Im Cannabis Corp requires distinguishing between market price and book value, where the latter reflects IMCC's accounting equity. The concept of intrinsic value—what Im Cannabis' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Im Cannabis' price substantially above or below its fundamental value.
Please note, there is a significant difference between Im Cannabis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Im Cannabis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Im Cannabis' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Net Income From Continuing Ops Analysis
Compare Im Cannabis Corp and related stocks such as Akanda Corp, Redhill Biopharma, and Shuttle Pharmaceuticals Net Income From Continuing Ops Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AKAN | (2.5 M) | (2.5 M) | (2.5 M) | (2.5 M) | (2.5 M) | (2.5 M) | (2.5 M) | (2.5 M) | (2.5 M) | (2.5 M) | (2.3 M) | (8.1 M) | (8.2 M) | (32.3 M) | (3.3 M) | (2.9 M) | (3.1 M) |
| RDHL | (10.6 M) | (10.6 M) | (10.6 M) | (10.6 M) | (10.7 M) | (21.1 M) | (29.4 M) | (45.5 M) | (38.8 M) | (42.3 M) | (76.2 M) | (97.7 M) | (71.7 M) | 23.9 M | (8.3 M) | (7.4 M) | (7.8 M) |
| SHPH | (805.7 K) | (805.7 K) | (805.7 K) | (805.7 K) | (805.7 K) | (805.7 K) | (805.7 K) | (805.7 K) | (805.7 K) | (805.7 K) | (805.7 K) | (1.2 M) | (3 M) | (5.7 M) | (9.1 M) | (8.2 M) | (7.8 M) |
| MOVE | (8.4 M) | (8.4 M) | (8.4 M) | (8.4 M) | (8.4 M) | (8.4 M) | (8.4 M) | (8.4 M) | (8.4 M) | (8.4 M) | (13 M) | (21.8 M) | (30.3 M) | (29.3 M) | (23.7 M) | (21.4 M) | (22.4 M) |
| JAGX | (25.5 M) | (8.6 M) | (8.6 M) | (8.6 M) | (8.6 M) | (15.8 M) | (14.7 M) | (22 M) | (32.1 M) | (38.5 M) | (33.8 M) | (52.6 M) | (48.4 M) | (40.8 M) | (39.3 M) | (35.3 M) | (37.1 M) |
| NDRA | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.3 M) | (2.8 M) | (5.4 M) | (9.8 M) | (13.3 M) | (11.7 M) | (11.2 M) | (13.2 M) | (11.9 M) | (11.5 M) | (10.4 M) | (10.9 M) |
| VERO | (21.8 M) | (21.8 M) | (21.8 M) | (21.8 M) | (21.8 M) | (21.8 M) | (21.8 M) | (17.8 M) | (28.7 M) | (42.3 M) | (82.8 M) | (22.1 M) | (43.6 M) | (35.8 M) | (47 M) | (42.3 M) | (44.4 M) |
Im Cannabis Corp and related stocks such as Akanda Corp, Redhill Biopharma, and Shuttle Pharmaceuticals Net Income From Continuing Ops description
My Equities
My Current Equities and Potential Positions
| Im Cannabis Corp | IMCC |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | Kibbutz Glil Yam, |
| Exchange | NASDAQ Exchange |
USD 1.21
Check out Im Cannabis Performance and Im Cannabis Correlation. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Im Cannabis technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.